Mesoblast provides update on progress of U.S. commercial launch of Ryoncil

Mesoblast (MESO) “provided an update on the progress of the U.S. commercial launch of Ryoncil, or remestemcel-L, for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline.”